Growth Metrics

Arcadia Biosciences (RKDA) Cash from Financing Activities (2016 - 2025)

Arcadia Biosciences' Cash from Financing Activities history spans 12 years, with the latest figure at $1000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 75.0% year-over-year to $1000.0; the TTM value through Dec 2025 reached $6000.0, down 33.33%, while the annual FY2025 figure was $6000.0, 33.33% down from the prior year.
  • Cash from Financing Activities reached $1000.0 in Q3 2025 per RKDA's latest filing, down from $5000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $22.0 million in Q1 2021 to a low of -$114000.0 in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $2.7 million, with a median of $5000.0 recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: plummeted 101.47% in 2021, then skyrocketed 137525.0% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$114000.0 in 2021, then surged by 4060.53% to $4.5 million in 2022, then tumbled by 99.84% to $7000.0 in 2023, then crashed by 42.86% to $4000.0 in 2024, then crashed by 75.0% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Cash from Financing Activities are $1000.0 (Q3 2025), $5000.0 (Q1 2025), and $4000.0 (Q3 2024).